Migraine

The AJMC® Migraine compendium is a comprehensive resource for clinical news and expert insights for the recurring type of headache, which is accompanied by side effects.

Latest News

Prior Authorization Requirements for Calcitonin Gene-Related Peptide Antagonists

April 20th 2023

This quantitative and qualitative analysis highlights differences in prior authorization requirements for migraine drugs from nearly 50 managed care organizations and summarizes broad types of criteria used.

Image of a hurting perosn
Care for Migraine Insufficient in Germany, Online Survey Finds

March 25th 2022

woman with migraine
Comparing Benign Recurrent Vertigo With Vestibular Migraine, Menière's Disease

March 21st 2022

tech
Machine Learning Could Help Predict Migraineur Response to NSAIDs

March 17th 2022

people in hospital
Examining Trends in Headache-Related ED Visits, Treatment

March 14th 2022

Acute Migraine Treatment: Prevalence and Classes of Agents

Experts in the management of migraine discuss the prevalence of individuals taking acute migraine therapy and enumerate the various classes of agents available.

Acute and Preventive Therapy for Migraine peer exchange

More News

All of the panelists for this series
January 20th 2021

Acute and Preventive Treatment: Differences and QOL Impact

Dr Rigmor Jensen Considers the Future of Research on Medication Overuse Headache
January 20th 2021

Dr Rigmor Jensen Considers the Future of Research on Medication Overuse Headache

It will be very interesting to understand the mechanism of medication overuse headache, along with the effects antibodies have on the condition, said Rigmor Jensen, MD, professor of neurology at The University of Copenhagen and director of the Danish Headache Center.
Graphic of headache
January 18th 2021

Data Show Migraineurs Who Respond to Triptans More Likely to Respond to Erenumab

Gianna Melillo
Compared with triptan nonresponders, patients with migraine who report a response to at least 1 triptan have a higher likelihood of responding to treatment with erenumab, according to real-world data published in The Journal of Headache and Pain.
New 5-Year Data Highlight Erenumab’s Efficacy, Safety
January 12th 2021

New 5-Year Data Highlight Erenumab’s Efficacy, Safety

Gianna Melillo
Erenumab treatment has been associated with reductions in migraine frequency and improvements in health-related quality of life that were maintained for at least 5 years, according to the results of an open-label treatment phase of a recent study.
Syringe and vial
January 11th 2021

What Are the Real-Life Effects of Erenumab Discontinuation?

Gianna Melillo
Data on patients with migraine who stopped erenumab treatment show that over half of patients had an early disease worsening while the remaining patients maintained their responder status during weeks 1 through 4 post treatment.
Dr Frank Porreca Talks Through the Challenges of Measuring Migraine Pain
January 6th 2021

Dr Frank Porreca Talks Through the Challenges of Measuring Migraine Pain

Pain is a subjective response with multiple features and components, said Frank Porreca, PhD, professor of pharmacology and anesthesiology at the University of Arizona and a member of the Department of Collaborative Research at Mayo Clinic in Arizona.
Study Compares Vertigo’s Effects on Patients With Vestibular Migraine, BPPV
January 4th 2021

Study Compares Vertigo’s Effects on Patients With Vestibular Migraine, BPPV

Gianna Melillo
The emotional, functional and physical effects of vertigo on patients with vestibular migraine were shown to be more significant compared with the experiences of patients with benign paroxysmal positional vertigo (BPPV) in a recent study.
Review Explores Association Between Migraine and Patent Foramen Ovale
January 1st 2021

Review Explores Association Between Migraine and Patent Foramen Ovale

Gianna Melillo
A “dose-response” relationship may exist between migraine and patent foramen ovale (PFO), according to a review published in Frontiers in Neurology.
Dr Peter McAllister Explains the Economic Benefits of Migraine Prevention
December 29th 2020

Dr Peter McAllister Explains the Economic Benefits of Migraine Prevention

Migraine accounts for many billions of dollars in direct and indirect health care costs, said Peter McAllister, MD, a neurologist, board certified headache specialist, and medical director of the New England Institute for Neurology and Headache.
Top 5 Most-Read Migraine Stories of 2020
December 25th 2020

Top 5 Most-Read Migraine Stories of 2020

Gianna Melillo
Our most-popular articles relating to migraine in 2020 included new research on menstrual migraine and the efficacy of erenumab, a calcitonin gene-related peptide inhibitor, for migraine.
Dr Stephen Silberstein on the Next Steps for Anti-CGRP Therapies
December 22nd 2020

Dr Stephen Silberstein on the Next Steps for Anti-CGRP Therapies

When it comes to the next steps for anti-CGRP therapies, we need to discuss the concept of synergism, said Stephen Silberstein, MD, professor of neurology at Thomas Jefferson University and director of the Headache Center at Jefferson Health.
Review Outlines Pharmacists’ Role in Migraine Management
December 15th 2020

Review Outlines Pharmacists’ Role in Migraine Management

Gianna Melillo
In a recently published review, researchers highlighted the disease burden of migraine, advances in preventive therapies, key takeaways from the most recent migraine management consensus statement, and advocated for increased pharmacist intervention in migraine medication management.
Post Hoc Analysis Finds Erenumab Enables Reversion From Chronic to Episodic Migraine
December 13th 2020

Post Hoc Analysis Finds Erenumab Enables Reversion From Chronic to Episodic Migraine

Gianna Melillo
The analysis, published in Cephalalgia, found that more than 50% of patients exhibited reversion from chronic migraine to episodic migraine after week 12 of the double-blind treatment phase.
Dr Faraidoon Haghdoost Discusses Next Steps for COVID-19, Migraine Research
December 9th 2020

Dr Faraidoon Haghdoost Discusses Next Steps for COVID-19, Migraine Research

The pandemic's effects on migraine need to be evaluated for the whole of 2020 and data from one specific time are not enough, said Faraidoon Haghdoost, MD, a general practitioner and PhD student at The George Institute for Global Health in Sydney, Australia.
Study Finds Migraine Is a Risk Factor for Peripheral Artery Occlusive Disease
December 7th 2020

Study Finds Migraine Is a Risk Factor for Peripheral Artery Occlusive Disease

Gianna Melillo
The presence of migraine is a significant risk factor for the development of subsequent peripheral artery occlusive disease, according to results of a retrospective cohort study published in the International Journal of Environmental Research and Public Health.
Dr Rigmor Jensen Dispels Common Misconceptions About Medication Overuse Headache
December 2nd 2020

Dr Rigmor Jensen Dispels Common Misconceptions About Medication Overuse Headache

Studies show giving preventive medication while taking away offending drugs is superior to continuing offending medication and adding preventive drugs in patients with medication overuse headache, said Rigmor Jensen, MD, professor of neurology at The University of Copenhagen and director of the Danish Headache Center.
Brain imaging
December 1st 2020

Review Evaluates Triggers of Pediatric Migraine

Gianna Melillo
Researchers assessed 3 risk factors for migraine in children and adolescents: stress, sleep poverty, and alimentation.
Obesity Associated With More Attacks, Separation Anxiety in Pediatric Migraineurs
November 28th 2020

Obesity Associated With More Attacks, Separation Anxiety in Pediatric Migraineurs

Gianna Melillo
Among children and adolescents suffering from migraine, results from a prospective study show being overweight is associated with a higher frequency of migraine attacks and separation anxiety symptoms.
Dr Frank Porreca Shares His Thoughts on Green Light Therapy for Migraine
November 27th 2020

Dr Frank Porreca Shares His Thoughts on Green Light Therapy for Migraine

If green light therapy were proven to be effective for migraine, it would be hugely important, said Frank Porreca, PhD, professor of pharmacology and anesthesiology at the University of Arizona and a member of the Department of Collaborative Research at Mayo Clinic in Arizona.
Dr Peter McAllister Shares How COVID-19 Altered Patients' Migraine Symptoms
November 18th 2020

Dr Peter McAllister Shares How COVID-19 Altered Patients' Migraine Symptoms

While migraine was more manifest in some patients during the pandemic, others were able to adopt healthier habits, said Peter McAllister, MD, a neurologist, board certified headache specialist, and medical director of the New England Institute for Neurology and Headache.
Study Finds Genetic Overlap Between Sleep Disturbances, Migraine
November 17th 2020

Study Finds Genetic Overlap Between Sleep Disturbances, Migraine

Gianna Melillo
The genetic determinants of sleep and migraine partly overlap, suggesting sleep disturbances may causally influence migraine etiology and could be targets for migraine treatment, according to results of a Mendelian randomization study.
Dr Stephen Silberstein Discusses Erenumab Use for Menstrual Migraine
November 11th 2020

Dr Stephen Silberstein Discusses Erenumab Use for Menstrual Migraine

If you only experience migraine with your period for a few days, it would be difficult to recommend taking a drug all the time, said Stephen Silberstein, MD, professor of neurology at Thomas Jefferson University and director of the Headache Center at Jefferson Health.
Syringe close-up
November 8th 2020

Study Points to Combined Efficacy of Erenumab, OnabotulinumtoxinA for Chronic Migraine

Gianna Melillo
Patients with chronic migraine who received a combination therapy of erenumab and onabotulinumtoxinA exhibited significant reductions in monthly headache days and monthly migraine days.
Dr Frank Porreca: How Advancements in CGRP Inhibitors Paved the Way for Migraine Prevention Therapies
November 4th 2020

Dr Frank Porreca: How Advancements in CGRP Inhibitors Paved the Way for Migraine Prevention Therapies

The CGRP story is really based on reverse translation and other observations in humans will be pursued along that same model, said Frank Porreca, PhD, professor of pharmacology and anesthesiology at the University of Arizona and a member of the Department of Collaborative Research at Mayo Clinic in Arizona.
Stethoscope and globe map
November 3rd 2020

Review Outlines Combined Genetic, Environmental Susceptibility to Vestibular Migraine

Gianna Melillo
Variability in prevalence of vestibular migraine, depending on ethnicity and geographic location suggests, a combined genetic and environmental contribution to VM, according to results of a systematic review.
Dr Faraidoon Haghdoost Explains Results of COVID-19 Migraine Triggers, Frequency Study
October 28th 2020

Dr Faraidoon Haghdoost Explains Results of COVID-19 Migraine Triggers, Frequency Study

There can be a myriad of reasons for the patterns observed in our study on alteration of migraine frequency and triggers during the pandemic, said Faraidoon Haghdoost, MD, a general practitioner and PhD student at The George Institute for Global Health in Sydney, Australia.
Researchers Show Brain Differences in 2 Different Types of Menstrual Migraine
October 26th 2020

Researchers Show Brain Differences in 2 Different Types of Menstrual Migraine

Gianna Melillo
In a study published in Scientific Reports, researchers highlighted structural and functional brain differences among those who suffer menstrual-related migraine (MRM) and pure menstrual migraine (PMM).
Dr Peter McAllister on How COVID-19 Has Impacted Migraine Prevention Efforts
October 22nd 2020

Dr Peter McAllister on How COVID-19 Has Impacted Migraine Prevention Efforts

Increased time spent in front of computer screens, less time spent sleeping, and less access to gyms have led my patients to have a lot more migraines, said Peter McAllister, MD, a neurologist, board certified headache specialist, and medical director of the New England Institute for Neurology and Headache.
Dr Messoud Ashina Talks Through the 5-Year Safety and Efficacy Data on Erenumab
October 19th 2020

Dr Messoud Ashina Talks Through the 5-Year Safety and Efficacy Data on Erenumab

Gianna Melillo
Data from a 5-year open-label treatment period on the safety profile of erenumab (Aimovig) showed the treatment helped patients with episodic migraine achieve a sustained reduction in the number of monthly migraine days and the number of days in which therapies were needed for acute migraines.
Study Describes Relationship Between Migraine, Postoperative Nausea and Vomiting
October 14th 2020

Study Describes Relationship Between Migraine, Postoperative Nausea and Vomiting

Gianna Melillo
Migraine is a significant risk factor for postoperative nausea and vomiting, according to results of a retrospective study published in the Journal of Clinical Medicine.
<123456789
...
17>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo